In the past year, Pfizer and AstraZeneca can be said to be "the fight" in the biomedical industry. Although Pfizer finally left the scene, it did not stop the biopharmaceutical giant from acquiring mergers and acquisitions. Recently, Pfizer said it will invest $87.5 million in the purchase of AM-Pharma shares in the Dutch biopharmaceutical company. However, Pfizer, which has already acquired “addiction”, has an alternative – $512 million to earn AM revenue.

Behind such a positive attitude of Pfizer, the company has taken a fancy to the new drug reCap developed by AM to treat acute kidney disease associated with septicemia. The new drug is an anti-inflammatory recombinant human alkaline phosphatase preparation, and AM has recently successfully completed a clinical phase II study of the drug. At the same time, analysts believe that this drug is expected to be the first approved drug therapy for the treatment of acute kidney injury associated with septicemia.

In January, AM announced its clinical phase II research plan for reCap and divided the entire clinical phase II study into two phases. In the first phase, 290 patients will be enrolled to determine the optimal dose of reCap; in the second phase, 170 patients will be involved to determine the creatinine clearance after seven days of drug treatment, and creatinine clearance is also a measure of the disease. . In addition, the researchers tracked the dialysis rate after 28 days of treatment and the protective effect of the drug on chronic kidney disease.

This time, Pfizer's active participation is clearly full of confidence in the clinical research of reCap. For a goal of sufficient value, Pfizer, which is rich in money, will definitely regard money as dirt. In fact, the $500 million acquisition fee is just a small deal for Pfizer. Earlier, it was reported that Pfizer offered $3.5 billion to acquire Swedish biopharmaceutical company Sobi to integrate its rare disease research and development system.

In addition, a few months ago, Pfizer and Merck signed a $850 million advance payment record for PD-L1 drug research. All of this indicates that for a long period of time, mergers and acquisitions will be one of Pfizer's priorities.

Auxiliary supplies for Livestock Reproduction

Livestock Reproduction Auxiliary Product,Blue Insert Split-Non Sheath,Agriculture Artificial Insemination Catheter,Length Pvc Pe Tube

Jinan Mucho Commercial Inc. , https://www.muchovet.com